GlassScriptPhysician profile
Joseph A Locke
NPI 1902078801
$1,012.29
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $218 · 2021: $280.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $336.08 | 2019-2021 | |
| Pfizer INC. | $152.91 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $149.90 | 2019-2021 | |
| Indivior INC. | $90.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.07 | 2019-2020 | |
| Uswm, LLC | $76.67 | 2021 | |
| Biodelivery Sciences International, INC. | $73.71 | 2019-2021 | |
| Gilead Sciences, INC. | $18.17 | 2021 | |
| Mdd US Operations, LLC | $16.37 | 2020 | |
| Fidia Pharma USA INC. | $15.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Locke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.